PARIS (Reuters) – A phase-3 study on the safety and efficacy of its ALTUVIIIO Hemophilia A treatment used for children met its primary endpoint, the French drugmaker said on Thursday.
“The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU,” Sanofi said in a statement.
Hemophilia A is a rare, lifelong condition in which the ability of a person’s blood to clot properly is impaired.
(Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)
